Kurt Cooper
National Institutes of Health
24 Papers
58 Citations
Kurt Cooper is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Virus & Ebola virus. The author has an hindex of 8, co-authored 17 publications.
Chat about Author
Papers
Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever.
Tiago Abreu-Mota,Katie R. Hagen,Kurt Cooper,Peter B. Jahrling,Gene Tan,Christoph Wirblich,Reed F. Johnson,Matthias J. Schnell +7 more
TL;DR: An inactivated, adjuvanted vaccine candidate expressing LASV glycoprotein (GPC) in a rabies virus vector is developed and it is shown that non-neutralizing L ASV GPC-specific antibodies are a major mechanism of protection.
A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene
Yíngyún Caì,Chengjin Ye,Benson Yee Hin Cheng,Aitor Nogales,Masaharu Iwasaki,Shuiqing Yu,Kurt Cooper,David X. Liu,Randy Hart,Ricky Adams,Tyler M. Brady,Elena Postnikova,Jonathan R. Kurtz,Marisa St. Claire,Jens H. Kuhn,Juan Carlos de la Torre,Luis Martinez-Sobrido +16 more
TL;DR: In this paper, a recombinant Lassa virus expressing a codon-deoptimized (CD) glycoprotein precursor gene (GPC), rLASV-GPC/CD, was generated and characterized.
42
A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence
Amy B. Papaneri,Christoph Wirblich,Jennifer A. Cann,Kurt Cooper,Peter B. Jahrling,Matthias J. Schnell,Joseph E. Blaney +6 more
TL;DR: The findings indicate that RV-GP retains the attenuation phenotype of the live-attenuated RABV vaccine, and RVΔG-GP would appear to be an even safer alternative for use in wildlife or consideration for human use.
32
An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models.
Reed F. Johnson,Drishya Kurup,Katie R. Hagen,Christine R. Fisher,Rohan Keshwara,Amy B. Papaneri,Donna L. Perry,Kurt Cooper,Peter B. Jahrling,Jonathan T. Wang,Jan ter Meulen,Christoph Wirblich,Matthias J. Schnell +12 more
TL;DR: The results demonstrate that the use of the synthetic Toll-like receptor 4 agonist glucopyranosyl lipid A in stable emulsion (GLA-SE) as an adjuvant increased the efficacy of FILORAB1 to 100% protection against lethal EBOV challenge, with no to mild clinical signs of disease.
Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein.
Amy B. Papaneri,Christoph Wirblich,Kurt Cooper,Peter B. Jahrling,Matthias J. Schnell,Joseph E. Blaney +5 more
TL;DR: The ability of these novel vaccines to induce strong humoral and cellular immunity indicates that they should be further evaluated in additional animal models of infection.
29